Vancomycin-induced ototoxicity in very-low-birthweight infants

Janina Marissen, Ingmar Fortmann, Alexander Humberg, Tanja K. Rausch, Arne Simon, Anja Stein, Thomas Schaible, Joachim Eichhorn, Jürgen Wintgens, Claudia Roll, Friedhelm Heitmann, Egbert Herting, Wolfgang Göpel, Christoph Härtel

Abstract

BACKGROUND: Vancomycin is an extensively used anti-infective drug in neonatal ICUs. However, exposure-toxicity relationships have not been clearly defined. OBJECTIVES: To evaluate the risk profile for hearing deficits in vancomycin-exposed very-low-birthweight infants (VLBWI). METHODS: In a large cohort study of the German Neonatal Network (GNN; n = 16 967 VLBWI) we assessed the association of vancomycin treatment and pathological hearing tests at discharge and at 5 year follow-up. We performed audits on vancomycin exposure, drug levels, dose adjustments and exposure to other ototoxic drugs in a subgroup of 1042 vancomycin-treated VLBWI. RESULTS: In the GNN cohort, 28% (n = 4739) were exposed to IV vancomycin therapy. In multivariable logistic regression analysis, vancomycin exposure proved to be independently associated with pathological hearing test at discharge (OR 1.18, 95% CI 1.03-1.34, P = 0.016). Among vancomycin-treated infants, a cumulative vancomycin dose above the upper quartile (>314 mg/kg bodyweight) was associated with pathological hearing test at discharge (OR 2.1, 95% CI 1.21-3.64, P = 0.009), whereas a vancomycin cumulative dose below the upper quartile was associated with a reduced risk of pathological tone audiometry results at 5 years of age (OR 0.29, 95% CI 0.1-0.8, P = 0.02, n = 147). CONCLUSIONS: Vancomycin exposure in VLBWI is associated with an increased, dose-dependent risk of pathological hearing test results at discharge and at 5 years of age. Prospective studies on long-term hearing impairment are needed.

OriginalspracheEnglisch
ZeitschriftThe Journal of antimicrobial chemotherapy
Jahrgang75
Ausgabenummer8
Seiten (von - bis)2291-2298
Seitenumfang8
ISSN0305-7453
DOIs
PublikationsstatusVeröffentlicht - 01.08.2020

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Vancomycin-induced ototoxicity in very-low-birthweight infants“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren